Parabon is using its Essemblix platform to develop drug compounds in therapeutic areas such as oncology and infectious disease. Current oncology compounds in preclinical development include treatments for glioblastoma multiforme (GBM) and prostate cancer.
With funding from the U.S. Department of Defense, Parabon is also developing synthetic vaccines — vaccines created purely through chemical synthesis to avoid the risks associated with current attenuated ("live") vaccines — with Ricin toxin as the first target pathogen.
The ability to rationally design and produce multifunctional compounds, where the relative location of each subcomponent is precisely determined, gives Parabon NanoLabs and its customers a compelling drug development advantage, and the ability to develop many types of drug compounds makes Essemblix a compelling platform.
Essemblix Products & Services
With Essemblix, we design and produce functional DNA-based nanostructures for ourselves and our customers.
Essemblix's "plug-and-play" molecular engineering makes it possible to create an enormous variety of multi-functional compounds. Functional subcomponents of Essemblix compounds include:
- cell-specific targeting agents
- therapeutic payloads, such as small molecules or siRNA
- imaging tracers; and,
- precisely patterned antigens for eliciting strong immune response.
Our Pharmaceutical Pipeline
P24RDN is designed for the treatment of GBM. Preclinical studies have demonstrated it to be safe and effective, and significantly increases survival in murine models hosting intracranial human glioma tumors.
PJ-01, which is being developed through a partnership with Janssen Pharmaceuticals, is designed for the treatment of prostate cancer. Preclinical studies are underway.
Using Essemblix, we can design and produce custom nanostructures to satisfy specific customer requirements. Example Essemblix applications include cell/tissue recognition, cell specific transfection, and targeted drug delivery.To learn more about our design and production services or explore partnership opportunities related to our product pipeline, contact us.
How Essemblix Works
Key to the approach is the use of synthetic DNA as a programmable molecular substrate. Although DNA is best known as a carrier of genetic information, strands of synthetic DNA can be constructed to have any sequence of bases (often represented by the letters A, C, G and T).
Because complementary sequences of DNA are mutually attractive, synthetic strands can be “programmed” with sequences that cause them to “swim to the right spot,” with respect to one another, and then bind to form nanostructures of virtually any shape. Before self-assembly is induced, DNA strands can be attached to other types of molecular subcomponents so that they are pulled into designated locations by the DNA strands during self-assembly.
The Parabon inSēquio™ Sequence Design Studio
The inSēquio Sequence Design Studio allows Parabon’s pharmaceutical engineers to graphically enter designs and then, using the extreme-scale computing capacity of Parabon's Frontier® Compute Platform, determines the optimal DNA sequences that will self-assemble into the specified design.
inSēquio's simple-to-use graphical editor allows nano-engineers to lay out a nanostructure visually. Users can rotate and bend strands, define bindings between base pairs, and copy and paste sequences and structures between design documents.